The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT) (INSTANT)
This study has been terminated.
(The study was stopped prematurely due to slow enrolment without code breaking.)
University of Turin, Italy
Information provided by (Responsible Party):
Giuseppe Biondi Zoccai, University of Turin, Italy
First received: October 6, 2011
Last updated: October 18, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||October 2009|
|Primary Completion Date:||October 2009 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, Petronio AS, Binetti G, Bolognese L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Am Heart J. 2012 May;163(5):835.e1-7. doi: 10.1016/j.ahj.2012.02.009.